UnknownNCT06131255

DRACULA1 Partum Depression: an Integrated Molecular-pharmaco-imaging Study")

This study has public registry information. It focuses on depression and currently lists study information in Italy.

DepressionObservationalFrom 18 Years to 40 Years

The study in practice

Understand this study

Listed age limits: 18 years to 40 years.

Compensation and expense reimbursement have not been verified for this summary.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateEstimated: January 1, 2024

Recruitment status: Unknown
Enrollment listed in the registry: 15
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sponsor type: Unknown or unclear
Study type: Observational
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: Italy
Age range: From 18 Years to 40 Years
Official registry ID: NCT06131255
Official title: ("The Role of the Glutamatergic Neurotransmission in Post- Partum Depression: an Integrated Molecular-pharmaco-imaging Study")

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT06131255. We help you review the study, but cannot decide medical eligibility.

Status unknown

Milan

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.

Does this study involve medication?

Yes. The study involves medication, including Citalopram.

Who can participate?

Listed age limits: 18 years to 40 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.